Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM

MPE Masterclass 2021 | The early detection and diagnosis of MGUS and SMMПодробнее

Progression and treatment of MGUS-SMM-MM & epigeneticsПодробнее

Understanding MGUS and SMM Progression - Irene Ghobrial, MD | MCRT Webcast September 26 (2/3)Подробнее

Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosisПодробнее

Risk Stratification for MGUS | Dr. S. Vincent Rajkumar | Oncology BrothersПодробнее

Early prevention of myeloma: dara for high-risk MGUS and low-risk SMMПодробнее

Should individuals diagnosed with MGUS or SMM be receiving bisphosphonates? #myelomaПодробнее

Early myeloma screening: an update on PROMISEПодробнее

Managing Your Pre-Myeloma Condition: MGUS, SMM, SBPПодробнее

NCCN Guidelines for Newly Diagnosed MMПодробнее

Redefining MGUS to better predict progression to active diseaseПодробнее

Updates in NCCN Guidelines for Molecular Testing in Prostate CancerПодробнее

Clonal evolution in MM: MGUS and SMMПодробнее

Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myelomaПодробнее

MGUS Diagnostic CriteriaПодробнее

Treating MGRS and MGUS with neuropathyПодробнее

How Sugar Impacts Multiple Myeloma, SMM and MGUSПодробнее

Genomic features of myeloma precursor conditions can predict clinical progressionПодробнее

iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021Подробнее